全文获取类型
收费全文 | 11340篇 |
免费 | 960篇 |
国内免费 | 230篇 |
专业分类
耳鼻咽喉 | 66篇 |
儿科学 | 223篇 |
妇产科学 | 59篇 |
基础医学 | 1478篇 |
口腔科学 | 478篇 |
临床医学 | 697篇 |
内科学 | 1122篇 |
皮肤病学 | 840篇 |
神经病学 | 781篇 |
特种医学 | 670篇 |
外国民族医学 | 6篇 |
外科学 | 1012篇 |
综合类 | 1075篇 |
预防医学 | 508篇 |
眼科学 | 745篇 |
药学 | 837篇 |
7篇 | |
中国医学 | 345篇 |
肿瘤学 | 1581篇 |
出版年
2024年 | 12篇 |
2023年 | 216篇 |
2022年 | 181篇 |
2021年 | 388篇 |
2020年 | 392篇 |
2019年 | 332篇 |
2018年 | 363篇 |
2017年 | 371篇 |
2016年 | 280篇 |
2015年 | 361篇 |
2014年 | 609篇 |
2013年 | 855篇 |
2012年 | 576篇 |
2011年 | 650篇 |
2010年 | 482篇 |
2009年 | 453篇 |
2008年 | 507篇 |
2007年 | 480篇 |
2006年 | 378篇 |
2005年 | 402篇 |
2004年 | 356篇 |
2003年 | 324篇 |
2002年 | 301篇 |
2001年 | 258篇 |
2000年 | 221篇 |
1999年 | 175篇 |
1998年 | 157篇 |
1997年 | 159篇 |
1996年 | 154篇 |
1995年 | 179篇 |
1994年 | 136篇 |
1993年 | 113篇 |
1992年 | 119篇 |
1991年 | 129篇 |
1990年 | 120篇 |
1989年 | 105篇 |
1988年 | 114篇 |
1987年 | 113篇 |
1986年 | 93篇 |
1985年 | 167篇 |
1984年 | 132篇 |
1983年 | 116篇 |
1982年 | 131篇 |
1981年 | 97篇 |
1980年 | 93篇 |
1979年 | 65篇 |
1978年 | 36篇 |
1977年 | 19篇 |
1976年 | 23篇 |
1975年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Cancer radiothérapie》2022,26(4):542-546
PurposeModerate hypofractionated radiotherapy has become routine practice for a selected population of patients treated for early-stage breast cancer. In April 2020, the Fast Forward (FF) study was published which introduced another extreme hypofractionated radiotherapy regimen in five sessions over a week. The aim of this work is to evaluate the population of first patients in whom this regimen was used in our department, as well as the results in terms of early toxicity.Material and methodsWe retrospectively analysed all the patients treated in our department according to the Fast Forward protocol after establishing an institutional consensus regarding the selection of patients with breast cancer without indication for lymph node irradiation. All patients received breast-only irradiation at a total dose of 26 Gy in five fractions according to protocol. All patients were treated by modern conformational techniques with planning large volume coverage between 95 and 100%. Acute toxicity of the treatment was assessed using the NCI CTC v4.0 scale and the general condition was assessed according to the WHO classification.ResultsBetween August 2020 and May 2021, 30 patients were included, treated on the breast alone without complement on the tumour bed or irradiation of the lymph node areas. The median age of the patients was 80 years (range: 60–85 years) with performance status 2 in 27 cases (89%). Only one patient had metastatic disease (3%), one patient presented locally advanced and 28 (94%) patients had early stage disease. Three patients (10%) were treated in dorsal decubitus according to the “field in the field” technique and 27 patients (90%) in isocentric lateral decubitus, which made it possible to avoid the organs at risk such as the heart (average dose of less than 1 Gy) and the lungs. The early toxicity observed was grade I radio dermatitis in 8 patients (27%). No grade 2 and 3 toxicity, as well as radiation-induced pain or lymphedema were observed.ConclusionsThe results of this series of patients treated with hypofractionated radiotherapy according to the Fast Forward protocol on the breast alone with adapted techniques show that the protocol is feasible, with little early toxicity but a greater follow-up is necessary to assess long-term toxicity. 相似文献
2.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
3.
4.
Nicolas Zhou Matthew Bott Bernard J. Park Eric Vallières Candice L. Wilshire Kazuhiro Yasufuku Jonathan D. Spicer David R. Jones Boris Sepesi 《The Journal of thoracic and cardiovascular surgery》2021,161(3):760-771.e2
BackgroundAdjuvant chemotherapy, postoperative radiation (PORT), and prophylactic cranial irradiation (PCI) have been individually examined in limited-stage small cell lung cancer (SCLC). There is a paucity of data on the effectiveness of each adjuvant treatment modality when used in combination after surgical resection of SCLC.MethodsData were collected from 5 cancer centers on all patients with limited-stage SCLC who underwent surgical resection between 1986 and 2019. Univariate and multivariable models were conducted to identify predictors of long-term outcomes, focusing on freedom from recurrence and survival benefit of adjuvant chemotherapy, PORT, and PCI.ResultsA total of 164 patients were analyzed. Multivariable Cox regression analysis did not identify any adjuvant therapies to significantly influence recurrence in this cohort. Specifically, PORT was not associated with a significant influence on locoregional recurrence and PCI was not significantly associated with intracranial outcomes. Adjuvant chemotherapy improved survival in all stage I through III disease (hazard ratio, 0.49; 95% confidence interval, 0.29-0.81; P = .005) and even in pathologically node negative patients (hazard ratio, 0.49; 95% confidence interval, 0.27-0.91; P = .024). Although PCI was found to improve survival in univariate analysis, it was not significant in a multivariable model. PORT was not found to affect survival on either univariate or multivariable analysis.ConclusionsThis is among the largest multi-institutional studies on surgically resected limited-stage SCLC. Our results highlight survival benefit of adjuvant chemotherapy, but did not identify a statistically significant influence from mediastinal PORT or PCI in our cohort. Larger prospective studies are needed to determine the benefit of PORT or PCI in a surgically resected limited-stage SCLC population. 相似文献
5.
6.
7.
8.
9.
10.
Yu A. Nakamura Shuhei Okuyama Aki Furusawa Tadanobu Nagaya Daiki Fujimura Ryuhei Okada Yasuhiro Maruoka Philip C. Eclarinal Peter L. Choyke Hisataka Kobayashi 《Cancer science》2019,110(12):3689-3694
Near‐infrared photoimmunotherapy (NIR‐PIT) is a molecularly targeted cancer phototherapy that is based on injecting a conjugate of a silicon‐phthalocyanine derivative, IRdye 700DX (IR700), and a monoclonal antibody that targets an expressed antigen on the cancer cell surface. Subsequent local exposure to NIR light results in the rapid and highly selective immunogenic cell death of targeted cancer cells. Because many cancers grow in bones through which light does not penetrate well, the goal of this study was to determine if NIR‐PIT can effectively treat cancers in bone. A bovine rib was used as a bone sample. Because the sample’s NIR light transmittance was shown to be approximately 4.52% in preliminary tests, it was hypothesized that a maximum radiation dosage of 128 and 1500 J/cm2 would be sufficient to induce cell death in in vitro target cells and in vivo mouse tumor models, respectively. Cell viability was measured through bioluminescence studies comparing relative luciferase activity, as well as a cytotoxicity assay. In the in vitro model, tumor cell viability was significantly decreased after 64 and 128 J/cm2 NIR light irradiation through the bone. An in vivo mouse tumor model also showed that 1500 J/cm2 NIR light irradiation through the bone significantly reduced tumor viability at both 24 and 48 hours posttreatment compared to the control group (P = .026 and .040 respectively). Therefore, despite limitations in light transmission, NIR‐PIT nevertheless is capable of effectively treating cancers within bone. 相似文献